Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway

Feng Ji1, Fan Zhang1, Miaomiao Zhang1, Kaili Long1, Mingyue Xia1, Fei Lu1, Enjie Li1, Jiannan Chen1, Jun Li2, Zhengliang Chen2, Li Jing2, Shaochang Jia3, Rong Yang4, Zhigang Hu1* and Zhigang Guo1*

Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited infiltration and persistence of CAR-T cells in the tumor microenvironment (TME). In this study, we screened a novel anti-CD70 scFv and generated CD70 CAR-T cells that showed effective antitumor functions against CD70+ renal carcinoma cells (RCCs) both in vitro and in vivo. We further evaluated the effect and explored the molecular mechanism of a PARP inhibitor (PARPi) in CAR-T cell immunotherapy by administering the PARPi to mouse xenografts model derived from human RCC cells. Treatment with the PARPi promoted CAR-T cell infiltration by stimulating a chemokine milieu that promoted CAR-T cell recruitment and the modulation of immunosuppression in the TME. Moreover, our data demonstrate that PARPi modulates the TME by activating the cGAS-STING pathway, thereby altering the balance of immunostimulatory signaling and enabling low-dose CAR-T cell treatment to induce effective tumor regression. These data demonstrate the application of CD70 CAR-T cell therapeutic strategies for RCC and the cross-talk between targeting DNA damage responses and antitumor CAR-T cell therapy. These findings provide insight into the mechanisms of PARPis in CAR-T cell therapy for RCC and suggest a promising adjuvant therapeutic strategy for CAR-T cell therapy in solid tumors.

Keywords: CAR, CD70, RCC, PARP, Renal carcinoma, Tumor microenvironment, cGAS-STING pathway

To the editor,
Chimeric antigen receptor T (CAR-T) cell therapy is emerging as a promising treatment and has achieved beneficial effects in cancer patients [1]. However, the application of CAR-T cell therapy for solid tumors (including renal cell carcinoma, RCC) has been hampered by numerous challenges [2]. It was determined that hematologic malignancies and solid tumors, including RCC, can constitutively overexpress CD70, which was shown to be an effective target of CAR-T cells in vitro and in vivo [3]. PARP inhibitors (PARPis), the cancer therapeutic agents targeting poly (ADP-ribose) polymerases (PARPs), which play a key role in the DNA damage repair process, have been reported to increase the recruitment of CD8+ T cells to the TME in mouse xenografts [4]. Here, we generated CD70 CAR-T cells with a novel efficient anti-CD70 scFv, and further investigated the effects and mechanisms of PARPi in regulating CAR-T cell therapy in RCC.

*Correspondence: huzg_2000@126.com; guo@njnu.edu.cn
1 Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210023, China
Full list of author information is available at the end of the article
Initially, we confirmed the elevated and specific expression of CD70 in RCC as well as in kidney cancer 786-0, A498, and 769-P cells, which paralleled the poor survival prognosis for renal cancer patients with high CD70 expression (Additional file 1: Fig. S1a–e). This result suggested that CD70 might be an effective target for CAR-T cell immunotherapy in RCC [3]. A second-generation humanized CAR was designed with a novel highly efficient anti-CD70 scFv that was identified from a human scFv phage display library, and the CAR sequence was subcloned into a lentivirus vector (Fig. 1a and Additional file 1: Fig. S2a–d). The percentage of stabilized positive cells was approximately 76% after infection for 12 days, and the defined CD4/CD8 T-cell ratio was 1:1 (Additional file 1: Fig. S2e–h) [5]. The CD70 expression was undetectable in both CD70 CAR-T cells and inactivated T cells, whereas it was detected in the CD3/CD28 antibody-activated T cells (Additional file 1: Fig. S2i, j).

![Image of Fig. 1](https://example.com/fig1.png)

**Fig. 1** PARP inhibitors promote tumor regression for RCC models under low-dose CD70 CAR-T cell treatment. 

- **a** Schematics of CD70-CARs incorporating different spacers (CD8α Signal peptide, CD8α Hinge, (G4S)3 Linker, and CD8α™™) and costimulatory domains (4-1BB).
- **b** Lysis of spheres of 786-0 target cell cultures in the presence of CD70 CAR-T cells, or Mock CAR-T cells (control) at a 1:1, 2:1, 4:1, 8:1 effector/target ratio. (Scale bar: 250 μm)
- **c** Real-time cytotoxicity assay (xCElligence RTCA SP) was used to evaluate the lysis of the indicated tumor cells when treated with mock CAR-T (E−) cells or CAR-T (E+) cells at the indicated E/T ratios over a 50-h period. Representative of three independent experiments.
- **d** ELISA results showed the IL-2, TNF-α and IFN-γ secretion levels by CD70 CAR-T (E+), mock CAR-T (E−) cells encountering 786-0 cell.

Subcutaneous renal cell carcinoma tumor (786-0) development was monitored by in vivo bioluminescence imaging (5 × 10^6 CAR-T cells/mice). Images taken at dpi. 0, 8, 10 are shown (exposure time of 40 s).

- **e** Kaplan–Meier survival curve was performed 140 days after 786-0 cells injection. Mice treated with CD70 CAR-T cells had a significantly longer survival probability in comparison with mice treated with PBS, T or mock CAR-T cells. **f** ELISA results showed the IL-2, TNF-α and IFN-γ secretion levels in mice blood treated by PBS, T, mock CAR-T, CD70 CAR-T cells.

Mice body weights monitored during treatment.

- **k** Kaplan–Meier survival curve was performed 150 days after 786-0 cells injection. Mice treated with CD70 CAR-T cells had a significantly longer survival probability in comparison with mice treated with T + Vehicle (DMSO), olaparib (OLA), T + OLA, CAR-T + Vehicle, CAR-T + OLA. **l** ELISA results showed the IL-2, TNF-α and IFN-γ secretion levels in mice blood treated by T+Vehicle, OLA, T+OLA, CAR-T + Vehicle, CAR-T + OLA. **m** CD70 CAR-T cells in peripheral blood were detected using flow cytometry on day 15 after CAR-T inoculation. All error bars represent SD. In all plots, ns, not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Next, we investigated the antitumor activity of our CD70 CAR-T cells in vitro and in vivo. CD70 CAR-T cells but not mock CAR-T cells induced significantly more target cell lysis of 786-0, A498, and 769-P cells than of HEK293 control cells (Fig. 1b, c and Additional file 1: Fig. S3a, b). Consistently, an increase in cytokines (IL-2, TNF-α, and IFN-γ) was observed in a coculture of CAR-T cells and CD70-positive tumor cells (Fig. 1d and Additional file 1: Fig. S3c). Notably, CD70 CAR-T cells induced a significant lytic effect on HEK293 cells but not on HEK293 cells, highlighting the antigen specificity of the target cell lysis (Additional file 1: Fig. S3d, e). Furthermore, mouse xenografts (derived from 786-0 cells) treated with CD70 CAR-T cells showed...
significantly decreased RCC burden and exhibited longer survival times than mice treated with PBS, T cells, or mock CAR-T cells (Fig. 1e–g and Additional file 1: Fig. S3f–h). Moreover, higher cytokine (IL-2, TNF-α, and IFN-γ) secretion levels were detected in the peripheral blood of mice treated with CD70 CAR-T cells than in the peripheral blood of mice treated with control vehicles (Fig. 1h). These results demonstrated that our CD70 CAR-T cells were effective in treating CD70+ RCCs in vitro and in vivo.

The PARPi olaparib (OLA) has been shown to improve the antitumor efficacy of CAR-T cells in breast cancer [6]. We further evaluated the effect of OLA in CAR-T cell therapy in RCC. We first explored the impact of OLA on CAR-T cells and found that OLA showed little effect on CAR-T cell viability when the OLA concentration was lower than 2.5 μM (Additional file 1: Fig. S4a, b). We then pretreated RCC cells with OLA following CAR-T cells incubation to detect the effect of OLA on different RCC cells. Cell apoptosis assays indicated that OLA pretreatment promoted the apoptosis of RCC cells but protected CAR-T cells against apoptosis (Additional file 1: Fig. S4c, d). Then, we designed an experimental scheme using mouse xenograft models treated with OLA and CAR-T cells (Fig. 1i). Notably, compared with the control treatments, the combinational treatment of OLA and CD70 CAR-T cells (CAR-T+OLA) showed more effective repression of RCC xenografts, which was accompanied by a better survival rate among tumor-bearing mice (Fig. 1j–m). The serum levels of TNF-α, IL-2, and IFN-γ were also higher in the CAR-T+OLA group than in the other four groups (Fig. 1n-p). Notably, CAR-T cells were observed on day 15 post CAR-T injection (dpi. 15) in the blood of the CAR-T+OLA group but not in the CAR-T+Vehicle groups (Fig. 1q), which further supported that OLA treatment promoted CAR-T cell persistence. Moreover, multicolor flow cytometry and IHC assays showed that OLA treatment increased the infiltration of CD8+ CAR-T cells but not CD4+ CAR-T cells and Treg cells in the TME 5 days after injection of CAR-T cells (Fig. 2a–c and Additional file 1: Fig. S5a, b).

Finally, to determine the molecular mechanism of OLA-induced cytotoxic CAR-T cell recruitment in the TME, we detected the activation of the cGAS/STING signaling pathway, which has been reported to be a critical activator in antitumor immune responses and in CD8+ T-cell recruitment with PARPi treatment [7, 8]. Elevated accumulation of cytosolic DNA and the DNA damage marker γH2AX was detected in 786-0 cells after treatment with OLA (Fig. 2d). The sensors and key regulators in the cGAS/STING pathway, including cGAS, and the phosphorylation of STING, TBK1, and IRF3, were all upregulated in cells treated with OLA, which was accompanied by upregulation of IFN-β expression (Fig. 2e and Additional file 1: Fig. S5c, d) [9]. The upregulation of IFN-β paralleled the observed increases in chemokines such as CCL5 and CXCL10, which are key mediators of the chemotaxis of CD8+ T lymphocytes (Fig. 2f–i and Additional file 1: Fig. S5e, f) [9, 10]. The increase in CD8+ CAR-T cells ultimately enhanced tumor lysis because of their secretion of large amounts of granzyme B (Fig. 2g, j) [11]. Moreover, knockdown of STING impaired the OLA-induced CCL5 and CXCL10 production in 786-0 cells (786-0shSTING) as well as in tumor tissues derived from 786-0shSTING cells, indicating that PARP inhibitor-induced proinflammatory cytokine production is mediated through the cGAS-STING pathway (Fig. 2k and Additional file 1: Fig. S6a–f). Notably, OLA-induced CD8+ CAR-T cell recruitment and granzyme B expression was abolished in the 786-0shSTING tumor tissues (Fig. 2k, l and Additional file 1: Fig. S6f, g). These data demonstrated that OLA-mediated CAR-T infiltration and persistence in TME are dependent on the cGAS-STING pathway [12].

In summary, we demonstrated the efficacy of CD70 CAR-T cells in RCC immunotherapy, and PARPi treatment enhanced this immunotherapy by promoting the infiltration of CD8+ CAR-T cells in the TME by activating the cGAS/STING signaling pathway (Fig. 2m). This study indicates that the combination of CAR-T cell therapy with PARPi represents a potential therapeutic approach for solid tumors.

**Abbreviations**
- CAR-T: Chimeric antigen receptor T-cell; TME: Tumor microenvironment; PARP: Poly ADP-ribose polymerase; RCC: Renal cell carcinoma; PARPi: PARP inhibitors; DC: Dendritic cells; OLA: Olaparib; PBMCs: Peripheral blood mononuclear cells; GFP: Green fluorescent protein; scFv: Single-chain variable fragment.

**Supplementary Information**
The online version contains supplementary material available at [https://doi.org/10.1186/s13045-021-01168-1](https://doi.org/10.1186/s13045-021-01168-1).

Additional file 1: Supplementary Figures.
Additional file 2: Supplementary materials and methods.

**Acknowledgements**
We thank every member of the laboratory for helpful comments and suggestions for this manuscript.

**Authors’ contributions**
FJ, ZG and ZH contributed to the conception and design; FJ, FZ, MZ, KL, MX, EL and JC contributed to the acquisition of data; JL, ZC and LJ contributed to the writing, review, and/or revision of the manuscript; FJ, FL, SJ, RJ, ZG and ZH contributed to the administrative, technical, or material support; ZG and ZH supervised the study. All authors read and approved the final manuscript.
Funding
This study was supported by the National Natural Science Foundation of China (81872284) and the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Availability of data and materials
The authors declare that all data supporting the results in this study are available within the paper and its supplementary information. Source data for the figures in this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
All in vivo animal experiments were approved by the Committee on the Ethics of Animal Experiments of Nanjing Normal University.

Consent for publication
Not applicable.

Competing interests
The authors have no conflicts of interest to declare.

Author details
1 Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210023, China. 2 Nanjing Blue Shield Biotechnology Co., Ltd., Nanjing 210023, China. 3 Jinling Hospital of Nanjing University, Nanjing 210002, China. 4 Department of Urology, Jinling Drum Tower Hospital, Nanjing 210008, China.

Received: 18 May 2021 Accepted: 14 September 2021 Published online: 23 September 2021

References
1. Sauter CS, Senechal B, Riviere I, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134:626–35.
2. Lesch S, Bennembarek MR, Cadiilha BL, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2020;65:80–90.
3. Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7–H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10:7622–34.
4. Pantelioudou C, Sonzogni O, De Oliveira TM, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722–37.
5. Gardner RA, Finney Q, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–31.
6. Sun R, Luo H, Su J, et al. Olaparib suppresses MDSC recruitment via SDF1α/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol Ther. 2021;29:60–74.
7. Guan J, Lu C, Jin Q, et al. MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021;39:100–21.
8. Li W, Lu L, Lu J, et al. cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy. Sci Transl Med. 2020;12:e9013.
9. Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–61.
10. Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142–9.
11. Liu Y, Fang Y, Chen X, et al. Gammadirin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5.
12. Xu N, Palmer DC, Robeson AC, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2021;218:e20200844.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.